Earnings Releases·Nov 3, 2026, 8:07 AM ET

Amneal Pharmaceuticals — Third Quarter 2026 Earnings Summary

Q3 2026 net revenue rose 10% year-over-year to $863 million, while adjusted EBITDA and adjusted diluted EPS increased 30% and 53% respectively to $207 million and $0.26; however, GAAP results shifted to a $22 million net loss due to $21.2 million in opioid settlement charges, $8.0 million in legal investigation costs, and $5.4 million in property losses.
Management raised full-year 2026 guidance across key metrics, increasing net revenue to $3.15–$3.25 billion, adjusted EBITDA to $800–$815 million, and adjusted diluted EPS to $1.04–$1.08, citing strong performance from new launches and the Kashiv integration.
The company completed the acquisition of Kashiv BioSciences, incurring $35.1 million in integration costs for the first nine months and borrowing an additional $350 million in August 2026, resulting in net debt of $3.07 billion and a net leverage ratio of 3.9x as of September 30, 2026.
Segment performance showed 19% and 20% revenue growth in Affordable Medicines and Specialty lines respectively, driven by biosimilars and branded products, while AvKARE revenue declined 17% due to a non-recurring prior-year launch.